Brief: Xpresspa Group And Ginkgo Bioworks Collaboration With CDC Covid-19 Biosurveillance Program Expands To Include Detection Of New Omicron Variant
30/11/2021 14:22
Nov 30 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :
* XPRESSPA GROUP AND GINKGO BIOWORKS COLLABORATION WITH CDC
COVID-19 BIOSURVEILLANCE PROGRAM EXPANDS TO INCLUDE DETECTION OF
NEW OMICRON VARIANT
Source text for Eikon: ID:nGNX7hYQ14
Further company coverage: DNA.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XWELL
See all newsMedia: Trump family-linked American Ventures backs XWell, a spa company offering medical screening- FT
Brief: Xwell Registers Resale Of Up To 138.7 Million Shares Of Common Stock From Time To Time By Selling Stockholders - SEC Filing
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:09 AM
NASDAQ RESUMED AT 09:57 AM